SELLAS Life Sciences Group (SLS) logo

SELLAS Life Sciences Group (SLS) stock

Cancer therapeutics , market cap $1.6B

After-hours
$17.90
-0.28%

Close $17.95 -6.27%

Why is SLS down?

Down 6.3% today, while its drugmaker peers are up 1.2%; no story names it yet.

Rose on Nov 17

Up 156% on Nov 17 while the S&P 500 fell 1%.

“SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically.”

Its release that day said

Sources: Price history, Nov 17, 2026; Company release (8-K), Nov 17, 2026

Tell me next time SLS moves

Free account, no card. An optional alert when SLS moves or its score changes.Pro, 7 days free with a card. An optional alert when SLS moves or its score changes.

Or see it live, free until Friday morning. No account.
1 more reason, free with an account →2 more reasons why SLS rose on Nov 17, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.
Quality Score
6
Average
In its industry
#27of 89
Checks firing
4of 14
Trending up
From 52-week high
-27.9%
under its best in a year

SLS's Quality Score fell 2 points on Wed, Nov 18, to 6.

Follow SLS's trial news. Pro members can get an alert when SELLAS Life Sciences Group files news, and see its trials, share raises, and its CEO's filings.

Get an alert when SLS files news on its trialsSee it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter…”Trial data · SEC filing · Nov 12
Cash$135M, about 19 quarters (5 years) at the last year's spendingOn Sep 30

Key facts on SLS

Key facts on SLS
The chartStronger than 99% of stocks above every average
Latest filing8-K, Nov 17 Issued a release: "SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically"
1 more reason behind SLS's 6, free with an account →5 more reasons behind SLS's 6, for Pro members.

SLS in the news

TodayNo story names it yet.

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Cash$135M, about 19 quarters (5 years) at the last year's spendingOn Sep 30

SLS catalysts

Coming up

After its last 4 reports it closed +5.3% on average, higher 2 of 4 times.

3 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for SLS, and how long its cash lasts

Next step the company has named

Q4 2026“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter.”Trial data · SEC filing · Nov 12

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
Tambiciclib
Another trial
SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLPhase 1/2 · Recruiting · 160 people · main data estimated Dec 30, 2026 · NCT04588922

1 more trial, 42 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 19 quarters

$135M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 20, 2026)
  • At-the-market share sales program (S-3ASR, filed Mar 20, 2026)

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Director Katherine Bach Kalin bought 63,400 shares on Nov 19, 2025.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Angelos Stergiou’s 10 filings and quotes.

Get an alert when SLS files news on its trialsA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 149 dates, ranked →

Why SLS scores 6

Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

  • +4Chart checks 4 of 14 firing right now, one point each
  • +3Long-term trend above a rising 200-⁠day average, at a multi-⁠year high
  • Run-up adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
  • News adds

No effect today: Size, Growth, and Persistence.

What every line is worth, and the reason behind it, on SLS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 7:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How SLS ranks in Pharma

SLS is #27 of 89 by Quality Score.

How SLS ranks in Pharma
RankStockQuality Score
27SELLAS Life Sciences Group (SLS) logoSLSSELLAS Life Sciences6

More in Pharma

When does SLS report earnings, and what happens after?

Expected to report Thu Mar 18, after the close (in 120 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What SLS reported on Nov 12, 2026

The quarter

A loss of $0.05 a share, from $0.06.

“The increase was primarily due to increases in manufacturing costs, clinical and regulatory consulting, and clinical trial expenses in preparation for a potential Biologics License Application (BLA) for GPS following the final analysis of the REGAL study.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

SLS's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase was primarily due to increases in non-cash stock-based compensation and professional fees.”

From its results filing (SEC filing · Nov 12)

2 more sentences, for Pro members.

The numbers

Market value
$1.6B
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on SLS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+25.1%+6.5%-2.1%
May 12Aug 11Nov 12
ReportedGapReaction5
days
Nov 12, 2026After close+8.2%-2.1%not yet
Aug 11, 2026After close+7.9%+6.5%+18.6%
May 12, 2026After close+21.0%+25.1%+45.4%

SLS closed higher after 2 of its last 4 reports.

All 4 reports, and SLS's Quality Score going into each

SLS has 4 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on SLS, and all 14 on every stock.Get in free →

SLS RSI today: 71.4, above its 50-day and 200-day averages

Not scored

RSI 71.4, MACD above signal, above both averages. Not scored.

The deep dive on SLS

10 more findings on SLS, each with its source, for Pro members.

SLS share count over time

87% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of SLS outstanding, as filed
Shares
outstanding
As
of
203.9MNov 11, 2026
201.9MAug 10, 2026
186MMay 11, 2026
179.6MMar 18, 2026
Offerings, shelves, and splits of SLS, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Mar 20, 2026
Priced a sale of sharesOct 27, 2025
Registered shares for a later sale (S-3)Oct 10, 2025
Priced a sale of sharesJan 29, 2025

4 more offerings on file, for Pro members.

SLS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold SLS?

In ETFs: SLS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

13 employeesNew York, NYsellaslifesciences.com

What SELLAS Life Sciences Group says it competes with

“While we believe that our scientific knowledge, assets, development experience and ability to attract experienced commercial professionals provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, which either alone or together with their collaborative partners, have substantially greater resources than we have.”

From its annual report, SEC filing · Mar 28, 2024

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on SLS and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move SLS's score: 7 things
  • 11 more filings explained, a plain line each
  • Real-⁠time prices, no delay
See SLS's 14 chart checks

See it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 18, 2026: SLS's Quality Score is 6 (Average), #27 of 89 in Pharma.

What does SLS's Quality Score say?

SLS scores 6 today, which Breakaway calls Average. It is #27 of 89 in Pharma by Quality Score, with 4 of 14 chart checks firing. Up 156% on Nov 17 while the S&P 500 fell 1%. Cash lasts about 19 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is SLS's Quality Score?

SLS scores 6 today, which Breakaway calls Average (6 to 10). That is #27 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind SLS's 6.

When does SLS report earnings?

Expected to report Thu Mar 18, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. SLS closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,147 stocks ranked

See it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for SELLAS Life Sciences Group: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.